Biosimilars 101

In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, guides listeners through the evolving landscape of biosimilars, highlighting their increasing presence in pharmacy practice and their critical distinctions from traditional generics. She explains the science behind biologics, the FDA’s rigorous approval process for biosimilars, and the nuances of interchangeability. With examples of biosimilars for Stelara, Humira, and Prolia, Vickie illustrates how pharmacists can confidently counsel patients, verify product details, and stay compliant with state laws. 

Whether you're stocking shelves or answering patient questions, this episode equips you with the knowledge to handle biosimilars with confidence, precision, and care.

This is an excerpt from our January 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Brush Up on Biosimilars
• FAQ: Facts About Biosimilars

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code podcast1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

****

Join the National Community Pharmacists Associations’ Annual Convention (NCPA) in New Orleans October 18-21st: https://bit.ly/ncpameeting25

****

If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.

Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

You can also reach out to provide feedback or make suggestions by emailing us at [e-mail].